OraSure Technologies Terminates Oral Fluid Drugs of Abuse Assay Collaboration With Roche Diagnostics

OraSure Technologies Terminates Oral Fluid Drugs of Abuse Assay Collaboration
With Roche Diagnostics

Updated Financial Guidance Announced for Fourth Quarter

BETHLEHEM, Pa., Nov. 21, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) announced today that its assay collaboration agreement with
Roche Diagnostics has been terminated. As part of the termination, Roche will
continue to supply certain of the assays developed under that collaboration on
a transitional basis for use with OraSure's existing Intercept^® collection
device.

Under the termination agreement, Roche will make an initial payment of $8.3
million to OraSure, will provide certain transitional product support services
and will continue to supply the five FDA-cleared assays for a period of up to
five years. OraSure has the right to stop the supply of assays prior to the
end of the five-year period and could receive payment of up to an additional
$5.5 million from Roche depending on how early in that five-year period the
supply obligation is ended.

OraSure also announced today
(http://phoenix.corporate-ir.net/phoenix.zhtml?c=99740&p=irol-newsarticle&ID=1878751)
that it has reached an agreement with another party to develop and supply up
to 12 homogenous fully automated oral fluid drugs of abuse assays to be used
with a new Intercept^® oral fluid specimen collection device. This new
agreement will replace the terminated collaboration with Roche. 

Updated Financial Guidance

As a result of the termination agreement announced today, the Company has
updated its financial guidance to reflect the initial payment expected from
Roche and is now projecting net income of $0.07 - $0.08 per share for the
fourth quarter of 2013.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market - making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their
health.

For more information on OraSure Technologies, please visit www.orasure.com.

Important Information

This press release contains certain forward-looking statements, including with
respect to product supply, certain payments and the Company's revenues and net
loss. Forward-looking statements are not guarantees of future performance or
results. Known and unknown factors that could cause actual performance or
results to be materially different from those expressed or implied in these
statements include, but are not limited to: ability to market and sell
products, whether through an internal, direct sales force or third parties;
ability to manufacture products in accordance with applicable specifications,
performance standards and quality requirements; ability to obtain, and timing
and cost of obtaining, necessary regulatory approvals for new products or new
indications or applications for existing products; ability to comply with
applicable regulatory requirements; changes in relationships, including
disputes or disagreements, with strategic partners or other parties and
reliance on strategic partners for the performance of critical activities
under collaborative arrangements; failure of distributors or other customers
to meet purchase forecasts or minimum purchase requirements for the Company's
products; impact of replacing distributors; inventory levels at distributors
and other customers; ability to integrate and realize the full benefits of the
Company's acquisition of DNA Genotek; ability of DNA Genotek to achieve its
financial and strategic objectives; ability to identify, complete, integrate
and realize the full benefits of future acquisitions; impact of competitors,
competing products and technology changes; impact of the economic downturn,
high unemployment and poor credit conditions; reduction or deferral of public
funding available to customers; competition from new or better technology or
lower cost products; ability to develop, commercialize and market new
products,including the OraQuick® In-Home HIV test; market acceptance of oral
fluid testing or other products; changes in market acceptance of products
based on product performance, extended shelf life or other factors; ability to
fund research and development and other products and operations; ability to
obtain and maintain new or existing product distribution channels; reliance on
sole supply sources for critical products and components; availability of
related products produced by third parties or products required for use of our
products; history of losses and ability to achieve sustained profitability;
ability to utilize net operating loss carry forwards or other deferred tax
assets; volatility of our stock price; uncertainty relating to patent
protection and potential patent infringement claims; uncertainty and costs of
litigation relating to patents and other intellectual property; availability
of licenses to patents or other technology; ability to enter into
international manufacturing agreements; obstacles to international marketing
and manufacturing of products; ability to sell products internationally,
including the impact of changes in international funding sources and testing
algorithms; adverse movements in foreign currency exchange rates; loss or
impairment of sources of capital;ability to retain qualified personnel;
exposure to product liability and other types of litigation; changes in
international, federal or state laws and regulations; customer consolidations
and inventory practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil unrest;
and general political, business and economic conditions. These and other
factors are discussed more fully in the Company's Securities and Exchange
Commission filings, including its registration statements, Annual Report on
Form 10-K for the year ended December 31, 2012, Quarterly Reports on Form
10-Q, and other filings with the SEC. Although forward-looking statements help
to provide information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. The forward-looking
statements are made as of the date of this press release and OraSure
Technologies undertakes no duty to update these statements.

CONTACT: Investor Contact:
         Ron Spair
         OraSure Technologies
         610-882-1820
         investorinfo@orasure.com
        
         Media Contact:
         Jennifer Moritz
         Zer0 to 5ive for OraSure Technologies
         917-748-4006
         jmoritz@0to5.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.